



## Compass Therapeutics to Participate in Upcoming November Investor Events

November 3, 2025

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November.

**Details are as follows:**

### **Guggenheim 2nd Annual Healthcare Innovation Conference**

**Location:** Boston, MA

**Date:** Monday, November 10, 2025

**Time:** 3:30 PM ET

**Webcast Link:** <https://event.summitcast.com/view/6h3HS7z68WnTQE5PS7Vq8J/Whrfp7V7J4xxPSb6WEtmkp>

### **Stifel 2025 Healthcare Conference**

**Location:** New York, NY

**Date:** Wednesday, November 12, 2025

**Time:** 4:00 PM ET

**Webcast Link:** <https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/PK2LUcfo5tANjQo7JVHDsB>

### **Jefferies Global Healthcare Conference**

**Location:** London, UK

**Date:** Thursday, November 20, 2025

**Time:** 12:00 PM GMT

**Webcast Link:** <https://wsw.com/webcast/jeff332/cmpx/1860808>

**Virtual/Replay availability:** Presentations will be archived for 90 days on Compass' [Events](#) page.

### **About Compass Therapeutics**

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

### **Investor Contact**

[ir@compasstherapeutics.com](mailto:ir@compasstherapeutics.com)

### **Media Contact**

Anna Gifford, Chief of Staff

[media@compasstherapeutics.com](mailto:media@compasstherapeutics.com)

617-500-8099